FONAR Corporation

FONR • Medical - Devices

$19.09

— 0.00 (0.00%)

Precio actual

ResultadosÚltimo reporte: 31 mar 2026

PERFIL EQUILIBRADONeutralConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil mixto. La empresa no es necesariamente mala, pero la valoración, el crecimiento o el balance todavía no justifican una señal más fuerte.

Capitalización

$120.19M

Crecimiento

2.0%

Flujo de caja

5/5

Tendencia

Stable

Evidencia

Flujo de caja libre positivo · 1.18Flujo de caja libre consistente · 5/5Múltiplo de ganancias razonable · 11.34Nivel de deuda manejable · 0.23Liquidez saludable · 8.45

Datos financieros hasta: 31 mar 2026, 12:00 a.m. UTCÚltima actualización de earnings: 11 may 2026, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:27 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$19.09

Change0.00%

Shares Out6.30M

Market Cap$120.19M

Enterprise Value$70.45M

52W Range13.62 - 19.16

Beta0.96

P/E17.97

P/S1.14

P/B0.67

P/FCF26.68

EV/Sales0.67

Price$19.09

Change0.00%

Shares Out6.30M

Market Cap$120.19M

Enterprise Value$70.45M

52W Range13.62 - 19.16

Beta0.96

P/E17.97

P/S1.14

P/B0.67

P/FCF26.68

EV/Sales0.67

EV/EBITDA5.02

EV/FCF15.64

Earnings Yield5.57%

FCF Yield3.75%

Dividend Yield0.00%

Gross Margin41.12%

Oper. Margin11.12%

Profit Margin7.99%

Debt/Eq0.23

Current Ratio8.45

Quick Ratio8.28

Revenue 5Y1.97%

Volume0.00

Avg Volume80.58K

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

49/100

Fortaleza financiera

Deuda, caja, estabilidad

95/100

Potencial de crecimiento

Ingresos y expansión

45/100

Atractivo del precio

Barata o cara hoy

92/100

Por qué este puntaje▼

Flujo de caja libre positivo · 1.18Flujo de caja libre consistente · 5/5Múltiplo de ganancias razonable · 11.34Nivel de deuda manejable · 0.23Liquidez saludable · 8.45

Analyst view

No analyst data available now.

Resumen de la compañía

IPO: 10/29/1981

Industria: Medical - Devices

P/B i: 0.67

Deuda / Patrimonio i: 0.23

Margen operativo: 11.12%

Margen neto: 7.99%

ROE i: -

ROIC: -

Salud financiera

Puntaje19 / 20

Deuda / Patrimonio: 0.23

Ratio corriente: 8.45

Ratio rápido: 8.28

Estado: Strong

Transacciones internas

Actividad reciente de ejecutivos e insiders

Lehman Ronald G.

Transacción: 06/03/2026

OTRO

Cambio

Precio

Not reported

Presentación

06/09/2026

Tipo

OTRO

Chan Claudette

Transacción: 06/23/2025

OTRO

Cambio

Precio

Not reported

Presentación

06/09/2026

Tipo

OTRO

Lehman Ronald G.

Transacción: 12/01/2020

COMPRA

Cambio

+2,629

Precio

Not reported

Presentación

06/09/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Lehman Ronald G.	OTRO	0	Not reported	06/03/2026	06/09/2026
Chan Claudette	OTRO	0	Not reported	06/23/2025	06/09/2026
Lehman Ronald G.	COMPRA	+2,629	Not reported	12/01/2020	06/09/2026
Lehman Ronald G.	COMPRA	+488	Not reported	07/17/2019	06/09/2026
Lehman Ronald G.	COMPRA	+363	Not reported	07/11/2018	06/09/2026
Lehman Ronald G.	COMPRA	+350	Not reported	06/21/2017	06/09/2026
Lehman Ronald G.	COMPRA	+500	Not reported	08/23/2016	06/09/2026
Lehman Ronald G.	OTRO	0	Not reported	04/23/2012	06/09/2026
Chan Claudette	OTRO	0	Not reported	10/15/1987	06/09/2026
Damadian Timothy Raymond	OTRO	0	Not reported	06/03/2026	06/08/2026
Bonanni Luciano B	OTRO	0	Not reported	06/03/2026	06/08/2026
Turk Richard E.	OTRO	0	Not reported	06/03/2026	06/08/2026
Maher Jessica	OTRO	0	Not reported	06/03/2026	06/08/2026
Carrino Robert M.	OTRO	0	Not reported	06/03/2026	06/08/2026
Carrino Robert M.	OTRO	0	Not reported	07/02/2025	06/08/2026
Maher Jessica	OTRO	0	Not reported	03/20/2023	06/08/2026
Damadian Timothy Raymond	COMPRA	+36,359	Not reported	11/08/2022	06/08/2026
Bonanni Luciano B	COMPRA	+8,066	Not reported	12/01/2020	06/08/2026
Turk Richard E.	OTRO	0	Not reported	06/04/2020	06/08/2026
Bonanni Luciano B	COMPRA	+7,455	Not reported	07/10/2019	06/08/2026

Sobre la compañía

FONAR Corporation

FONAR Corporation, along with its affiliated entities, is primarily engaged in the research, development, manufacturing, and commercialization of magnetic resonance imaging (MRI) systems within the United States. These sophisticated scanners are instrumental in the detection and diagnosis of various human diseases. The company's operations are divided into two distinct divisions: a Medical Equipment segment and a Physician Management and Diagnostic Services segment. A flagship product is their innovative Upright MRI scanner, which offers the unique capability of imaging patients in weight-bearing postures such as standing, sitting, bending, or traditional supine positions. This allows for the observation of conditions that manifest under natural gravitational stress. Furthermore, under its Physician Management segment, FONAR provides a comprehensive suite of non-medical management and administrative support services. These encompass areas like billing and collections, professional credentialing, contract negotiation, compliance consultation, IT procurement, human resources (including hiring, training, and supervision of non-clinical staff), medical record archival, office space and equipment provision, maintenance, accounting, and assistance with regulatory adherence, as well as the formulation and execution of practice growth and marketing initiatives. FONAR maintains a significant presence in diagnostic imaging services, directly owning and operating five facilities in Florida. Additionally, it oversees the management of 39 MRI scanning centers, with 25 located in New York and 14 throughout Florida. The company strategically markets its advanced MRI technology to both independent diagnostic imaging centers and hospitals. Incorporated in 1978, FONAR Corporation is headquartered in Melville, New York.

Fuente - Link

Competidores

APYX ARTV EDAP HYPR IFRX LUNG NSPR QIPT RCEL VANI

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

The Wagner Firm Announces Investigation Regarding FONAR Corporation

LOS ANGELES--(BUSINESS WIRE)--The Wagner Firm announces that it is investigating potential breaches of fiduciary duty regarding the take-private merger of FONAR Corporation (FONR), which was acquired by a management-led group.Our investigation focuses on whether public shareholders received fair value for their shares. The consideration rates for the merger were $19.00 for common/Class B stock, $6.34 for Class C stock, and $10.50 for Class A preferred stock. Following the transaction, FONAR was.

Business Wire